关于收到国家知识产权局《无效宣告请求审查决定书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 深圳微芯生物科技股份有限公司（以下简称"公司"）于近日收到中华人民共和国国家知识产权局（以下 简称"国家知识产权局"）出具的《无效宣告请求审查决定书》（第589684号）。国家知识产权局专利局 复审和无效审理部对无效宣告请求人南京正大天晴制药有限公司提出的公司所持有的"一种E构型苯甲 酰胺类化合物及其药用制剂与应用"（专利号：ZL201410136761.X）的专利权之无效宣告请求进行了审 查，审查结论为宣告专利权全部无效。现将有关情况公告如下： 证券代码：688321 证券简称：微芯生物 公告编号：2025-058 深圳微芯生物科技股份有限公司 案涉专利系公司产品西达本胺的外周T细胞淋巴瘤适应症专利，公司围绕西达本胺已形成化合物、晶 型、关键工艺、制剂、适应症等多项专利共同构建的专利保护体系，最长专利保护期已延长至2042年8 月30日。案涉专利属于西达本胺专利保护体系中的适应症专利之一,该适应症专利被宣告无效，并不意 ...

Core Viewpoint - The company, Nanwei Medical Technology Co., Ltd., is currently involved in a patent invalidation request initiated by Beijing Zhongke Shengkang Technology Co., Ltd., which may impact its patent rights and potential compensation from a previous infringement lawsuit [1][2]. Group 1: Case Background - The case is at the stage of acceptance and has not yet been reviewed [1]. - The company is the patent holder involved in the dispute [1]. - The patent in question is for a hemostatic clip (Patent No. 201410222753.7), which was applied for on May 23, 2014, and granted on November 18, 2015 [2]. Group 2: Previous Litigation - The company initiated a patent infringement lawsuit against Zhongke Shengkang, which resulted in a ruling that found Zhongke Shengkang guilty of infringement, ordering them to cease infringing activities and pay the company 700,000 yuan [2]. - Zhongke Shengkang has appealed the first-instance judgment to the Supreme People's Court, and the case is still under review [2]. Group 3: Impact on Company - If the patent is ultimately declared invalid, competitors may use the technology without compensation to the company, affecting the potential recovery from the previous lawsuit [1][3]. - The company asserts that the invalidation of the patent will not significantly impact its production and sales, as it has a robust core technology system that includes multiple patents and technical know-how [4]. - The company reported that its domestic sales of products utilizing the disputed patent were approximately 100 million yuan in 2024 [3].